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ABSTRACT Assessment of disease burden and drug efficacy is achieved preclinically using high resolution
micro computed tomography (CT). However, micro-CT is not applicable to clinical human imaging due to
operating at high dose. In addition, the technology differences between micro-CT and standard clinical CT
prevent direct translation of preclinical applications. The current proof-of-concept study presents spectral
photon-counting CT as a clinically translatable, molecular imaging tool by assessing contrast uptake in
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an ex-vivomousemodel of pulmonary tuberculosis (TB). Iodine, a common contrast used in clinical CT imaging, was
introduced into a murine model of TB. The excised mouse lungs were imaged using a standard micro-CT subsystem
(SuperArgus) and the contrast enhanced TB lesions quantified. The same lungs were imaged using a spectral photon-
counting CT system (MARS small-bore scanner). Iodine and soft tissues (water and lipid) were materially separated,
and iodine uptake quantified. The volume of the TB infection quantified by spectral CT and micro-CT was found
to be 2.96 mm3 and 2.83 mm3, respectively. This proof-of-concept study showed that spectral photon-counting CT
could be used as a predictive preclinical imaging tool for the purpose of facilitating drug discovery and development.
Also, as this imaging modality is available for human trials, all applications are translatable to human imaging. In
conclusion, spectral photon-counting CT could accelerate a deeper understanding of infectious lung diseases using
targeted pharmaceuticals and intrinsic markers, and ultimately improve the efficacy of therapies by measuring drug
delivery and response to treatment in animal models and later in humans.
INDEX TERMS High resolution, translatable molecular imaging, photon-counting spectral CT, pulmonary
tuberculosis, micro-CT.
I. INTRODUCTION
According to the World Health Organization, mycobac-
terium tuberculosis (TB) is a worldwide health problem, with
10 million new TB cases and 1.3 million deaths recorded
in 2019 alone [1]. Drug-resistant TB strains remain a pub-
lic health crisis threat and account for 3.3% of TB-related
deaths [2]–[4]. Extensive efforts to curb TB and TB drug
resistance via novel therapies have resulted in a decline in TB
incidence of approximately 2% per year. However, decreas-
ing incidence rates must accelerate in order to reach targets
set by the Sustainable Development Goals (SDG) [1].
Clinical trials examining new TB treatments are lengthy
and complex, suffer from poor patient compliance, and
require long periods of follow-up to assess the patient’s
response to treatment [1], [5], [6]. Therefore, uncertainty sur-
rounding the optimal combination of drugs and doses to effec-
tively treat patients is a major cause of efficacy assessment
failure [5], [6]. Consequently, predictive preclinical imaging
plays a vital role in facilitating the development of novel
drug regimens and preclinical efficacy studies using animal
models of disease is key to supporting the rationale of clinical
trials involving patients [7].
Micro-CT is widely used in preclinical laboratories for
non-invasive, high-resolution anatomical imaging in animal
models of disease [8], [9]. Micro-CT can provide insights
into new applications for clinical CT. However, micro-CT is
limited by the associated high radiation dose and technology
differences. In other words, scaling up micro-CT to human
imaging would result in harmful exposure levels, therefore,
preventing direct translation of micro-CT findings to clin-
ical CT [8], [9]. Furthermore, A relatively large number
of subjects and sacrifices at each time point are necessary,
imposing constraints on the ethical feasibility and efficacy of
such preclinical investigations. Moreover, pharmacodynamic
(PD) endpoints in preclinical investigations (involving animal
models) are commonly expressed as proportions of in-vitro
culture negative at a limited number of time points [10]–[12].
These results do not reflect outcomes in humans due to the
variability in the level of bacillary replication and recurrence
induced by non-standardized experimental conditions [11].
Preclinical imaging that uses the same technologies, in terms
of hardware and software, as for clinical imaging would
result in a more rapid translation [12]–[14]. Thus, spectral
photon-counting (CT) should be considered as a translatable
technique.
Spectral photon-counting CT is an advanced technique that
increases contrast resolution in soft-tissue using novel prop-
erties of a photon-counting detector [13], [15]. The spectral
scanner employed in this study is the MARS spectral CT
system (MARS-11 V5.1 (2016) S/N:11, MARS Bioimaging
Ltd, New Zealand), which is equipped with the Medipix3RX
photon-counting detector [17], [18]. The Medipix3RX detec-
tor developed at CERN (The European Organization for
Nuclear Research) comprises a cadmium zinc telluride semi-
conductor sensor layer, plus readout electronics for measur-
ing up to eight energies at high resolution (50-200 µm).
Three counters operate in single pixel mode, one counter is
an arbitration counter, and four energy counters operate in
charge summingmode (CSM). CSM refers to communication
between pixels, where an incidental charge cloud spread over
neighboring pixels is summed and allocated to the pixel
that registered the highest charge. This technique minimizes
the effect of charge sharing when using very small pixels
(110µm), which improves energy and spatial resolution [19].
The four counters operating in CSM were used in the current
study. Photon energy measurements, combined with known
attenuation energy dependence in different materials, result
in the simultaneous differentiation and quantification of up to
six materials [15], [20]. Spectral photon-counting CT imag-
ing with the MARS scanner has proven useful in a wide
range of preclinical applications pertinent to common human
conditions, including crystal arthropathies [21], atherosclero-
sis [22], bone health [23]–[25], and cancer [26], [27]. Studies
have also used MARS spectral imaging to investigate novel
targeted pharmaceuticals, such as hafnia-based nanoparti-
cles that have been chemically trained to highlight bone
microdamage [23], [26].
To demonstrate how spectral photon-counting CT can
facilitate drug dose optimization via molecular imaging,
an iodine-based contrast agent was administered to a murine
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model of TB and scanned using a spectral photon-counting
CT scanner. Iodine was chosen because it is an easily acces-
sible, standard X-ray imaging contrast agent. Measurement
of the healthy and disease-related lung tissue volume by
the spectral CT was compared to quantification performed
on the same lungs by high-resolution micro-CT subsystem
(SuperArgus scanner, Sedecal Molecular Imaging Madrid),
optimized for soft-tissue imaging tasks [28]. Spectral photon-
counting scanners provide human translatable preclinical
molecular imaging, simultaneous measurements of multiple
materials, the potential for the non-invasive assessment of
PD endpoints, and higher energy and spatial resolution at
greater sensitivity. This proof-of-concept study is the first
step in being able to diagnostically target TB lung infection
and quantify drug delivery. The unique properties of photon-
counting technology combined with a high-Z contrast mate-
rial attached to a biomarker and/or anti-TB drug will enable
molecular imaging that could facilitate drug development.
II. MATERIALS AND METHODS
A. LUNG SAMPLE PREPARATION
The current research was based on excised whole organs
from procedures approved by the Animal Experimentation
Ethics Committee of Hospital General Universitario Gregorio
Maran, Madrid, Spain and performed according to EU direc-
tive 2010/63/EU and national regulations (RD 53/2013).
The mouse lung tissue examined were from two females
of the C57BL/6J strain. One mouse was inoculated with
virulent TB H37Rv strain via exposure to aerosol infection
(dose 100 colony forming units) at the age 8-12 weeks. Both
animals were euthanized eight weeks following the intra-
tracheal insult using CO2 gas. At that time, chronic TB was
established, and well-formed lesions were present (animals
were euthanized prior to the development of calcification).
Prior to lung tissue extraction, the animals received 15 mL
of 10% formalin through the trachea. To retain the formalin
solution within the lungs, a thoracic opening was made, and
the lungs were closed at the top and bottom by a thread.
Once fixed, the lungs were extracted and placed into 10%
formaldehyde for at least 18 days to ensure deactivation of
the TB infection.
B. LUNG SAMPLE STAINING
The tissue samples underwent a fixation procedure (graded
ethanol concentration fixation: GECF) prior to staining with
contrast. The purpose of the GECF protocol, described
in [29], was to increase the absorption of contrast. One
healthy mouse lung and one TB-infected lung were immersed
in iodine (I2; Sigma-Aldrich Co.) in a 3% w/v ethanol solu-
tion for 2 hours. The lungs were kept inflated at a constant
pressure of 20 cm H2O during the GECF and staining pro-
cesses to prevent abrupt shrinkage and ensure homogeneous
uptake. Following the staining process, the lungs were fixed
in paraffin. Paraffin fixation provides the opportunity to cut
the lungs for histological examination. A tinfoil layer was
TABLE 1. Summary of acquisition parameters for pulmonary task using
MARS-11 (V5.1 (2026) S/N:11) and Micro-CT subsystem of super argus.
used to cover the bottom of the paraffin cassette measuring
5 cm (w) x 7 cm (l) x 1.5 cm (d). A total of 104 mL of heated
paraffin was used to embed the TB-infected and healthy lung
samples separately. Paraffin blocks were left to cool and
harden for 24 hrs before imaging. The purpose of paraffin
fixing was to enable a direct comparison between micro-CT
and spectral CT images [30].
C. LUNG IMAGING
A summary of the imaging protocols employed for the
micro-CT (SuperArgus scanner, Sedecal Molecular Imaging
Madrid) and spectral CT (MARS-11 scanner V5.1 (2016)
S/N:11, MARS Bioimaging Ltd, New Zealand) are shown
in Table 1. The acquisition protocol for the micro-CT was
optimized (in terms of beam conformation) for enhanced
soft-tissue contrast [10]. The micro-CT is based on an
energy-integration detector therefore has one energy range.
Pulmonary imaging tasks required copper filtration with a
peak voltage of 65∼70 kVp. Given that this protocol is also
used for in-vivo imaging, a compromise between image reso-
lution and total acquisition time was taken into consideration.
For an equivalent acquisition protocol to that of the micro-
CT, the spectral CT X-ray source tube was operated at
a constant peak voltage of 60 kVp and the tube current
increased to 90 µA, with 3.8 mm total aluminum X-ray beam
filtration. Energy thresholds were appropriately selected to
perform material decomposition (MD) of iodine, a second
high-Z contrast (silver nitrate), and soft tissues (water and
lipid). Silver nitrate was included in this phantom for a
distinguishing point. Protocol optimization for the simulta-
neous differentiation of iodine and silver in a calibration
phantom and lung tissue samples (in ethanol) is supplied in
the supplementary material. Four energy bins in CSM were
used. The energy thresholds selected were: 20, 27, 34, and
45 keV.Material calibration provides protocol-specific detec-
tor responses (spectral and linearity responses) that enable
accurate identification and quantification of the calibrated
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FIGURE 1. Left: Picture of the PMMA calibration phantom containing
200 µL Eppendorf tubes of iodine solutions (2.25, 4.5, 9, and 18 mg/mL),
lipid (L), water (W), and silver nitrate solutions (2, 4, and 8 mg/mL). Silver
nitrate was included in this phantom for imaging for a distinguishing
point. Protocol optimization for the simultaneous differentiation of
iodine and silver in a calibration phantom and lung tissue samples (in
ethanol) is supplied in the supplementary material. Right: A schematic of
the calibration phantom.
materials. A PMMA (Polymethyl methacrylate) calibration
phantom containing 200 µL vials of water, lipid, and iodine-
based solutions (2.25, 4.5, 9, and 18 mg/mL) was scanned.
The calibration phantom is shown in Fig. 1. The mass attenu-
ation values were obtained from analysis of the calibration
phantom vials using an in-house program [31], [32]. MD
was applied to the reconstructed linear attenuation volumes
for each energy window of the phantom vials and excised
lungs. The performance of the MD step was assessed by
measuring material identification and quantification success
of the iodine vials.
D. TISSUE ANALYSIS
Segmentation of the lung damage caused by the TB infec-
tion in standard PET/CT and CT images is performed using
thresholding methods, such as that described in [33]. This
method uses an automated algorithm that extracts the vol-
ume of the damaged lung tissue using Hounsfield Unit (HU)
values that reveal abnormal densities associated with disease.
A similar thresholdingmethodology was later applied in [34],
where accurate CT segmentation of the disease-associated
tissue could be aided using histological analysis.
For this study, histograms of the lung voxels in HU (micro-
CT) or iodine concentration (spectral CT) were exported for
the healthy lung. The greatest density (HU) or concentration
(mg/mL) within the healthy lung dataset was found. For
micro-CT, a 5% margin of error, established by [34], was
added and the new HU value was used as the threshold
between healthy and disease-related lung tissue. For spectral
CT, the variation in measured iodine concentration (Fig. 7)
was assessed. A positive linear relationship (r = 0.98) was
found between iodine concentration and standard error. The
positive linear relationship was used to find the standard
error at the concentration of iodine that separated healthy and
disease-related tissue (24.4 mg/mL). The calculated standard
error was added to this threshold. Table 2 provides a summary
of the thresholding values used to segment the background,
healthy tissue, and disease-related tissue for quantification
measurements by photon-counting CT and by micro-CT.
Lung volumes were calculated by summing the volume of
voxels whose values fell within the established thresholds.
TABLE 2. Thresholds for tissue segmentation.
FIGURE 2. MARS energy images in HU of the phantom detailed in
Fig. 1 for each energy bin.
FIGURE 3. Spectral response of the detector for iodine calibration
phantom vials and lipid. Enhancement of attenuation is observed (for all
iodine concentrations) in energy bin three (34-45 keV), which indicates
the K-edge of iodine. The standard errors for each data point are in the
range of 1-10 HU.
III. RESULTS
A. MARS SPECTRAL CT CALIBRATION
PHANTOM ANALYSIS
Fig. 2 shows one reconstructed slice of the calibration phan-
tom in each energy bin. The unique spectral response for
the iodine calibration vials and lipid are included in Fig. 3.
The K-edge of iodine was detected as a peak in attenuation
in the third energy bin (34-45 keV) for every concentration.
Fig. 4 displays the measured linearity of attenuation in each
energy bin for the iodine solution.
Fig. 5 illustrates the detection of iodine in the iodine-
based solutions, water, lipid, and the second high-Z contrast
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FIGURE 4. The linearity of attenuation for iodine is established via the
calibration phantom. Linear regression lines are displayed on the graph.
r2 = 0.99 for all energy bins. The standard errors for each data point are
in the range of 2-6 HU.
FIGURE 5. Material decomposition of the PMMA calibration phantom
views using MARS Vision (in-house visualization software). Four datasets
shown: iodine (orange), lipid (beige), silver nitrate (white), and water
(semi-transparent blue).
material for a distinguishing point. Iodine identification
success is greater than 99.5% for all iodine concentra-
tions. That is, 99.5% of voxels within the iodine vials
were correctly identified as iodine. An identification success
of 80% or greater is considered good material decomposition
performance [32].
Each calibration vial was quantified in the MD and
compared to the actual known concentration, as shown
in Fig. 6. The comparison provides validation regarding
iodine measured in the lungs. In addition, the margin of
error for tissue segmentation using the spectral CT data was
established using the quantification data (see methods). The
linearity of attenuation was established in each energy bin,
thus, the measured iodine presented comparable results. This
provides confidence that the stained concentration (in the
lung samples) and concentration measured using the spectral
CT will be comparable.
B. MARS SPECTRAL CT VS SUPERARGUS MICRO-CT
Due to the whole organ uptake of iodine, the iodine concen-
tration was normalized to 0 mg/mL. The threshold between
healthy tissue and background was considered 0 mg/mL of
iodine (Table 2).
Using in-house visualization software (MARS Vision),
Fig. 7 displays three-dimensional (3D) data obtained by
FIGURE 6. Measured concentration from MARS MD on the y-axis and the
known concentration on the x-axis. Iodine shows comparable values;
therefore, we can be confident that what is measured in the biological
specimen will be comparable to what is present in the organ. Variance
shown.
FIGURE 7. Visualization using MARS Vision was performed. (a) Micro-CT
energy data of healthy lung and (b) TB-infected lung used HU values and
thresholds shown in Table 2 to visualize the lungs. (c) The water channel
and iodine channel with thresholds applied shows the healthy lung with
no iodine above 27.8 mg/mL. The magic lens tool reveals one region of
interest. However, it is important to note there is no iodine present
<27.8 mg/mL throughout the lung, there are no lesions. (d) Similarly,
the water channel and iodine channel show the TB-infected lung. The
lesions can be viewed using the magic lens which removes the water
channel in a region of interest. The lipid channel is not shown since
concentration was measured to be zero (no fat within the mouse lungs as
expected).
the micro-CT (top) and data obtained by the spectral CT
(bottom). There was some collapse of lung tissue due to
the paraffin fixing process [30]. The threshold computed for
tissue analysis was applied to the iodine material dataset
of the healthy and TB-infected lung images. The result is
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no iodine was visualized in the healthy lung, as shown by
the MARS Vision magic lens tool in Fig. 7c. The magic
lens tool is used to remove one or more material channels.
In this case, the water channel is removed to observe the
highest concentrations of iodine. Iodine concentration above
the threshold that is visualized in the TB-infected lung is
associated with disease-related tissue (orange). Higher con-
centrations of iodine helped locate TB lesions and quantify
infection.
The healthy lung volume was quantified: 44.6 mm3 and
49.7mm3 for the spectral CT andmicro-CT, respectively. The
TB-infected lung was quantified: healthy tissue was found to
be 38.18 mm3 and 47.24 mm3 for the spectral CT and micro-
CT, respectively. The volume of disease-related tissue was
found to be 2.96 mm3 and 2.83 mm3 for the spectral CT and
micro-CT, respectively.
Histology provides the ground truth to check for correla-
tion between images and histological cuts. The methods we
followed for guiding histology are well established [28], [30],
[35]. The results of the histological images confirmed lesion
location. That is, our expert confirmed that the lesions located
by spectral CT and micro-CT were visualized in histology.
Also, lesions were not found in the healthy (control) lung
tissue. Histological slides are available in the supplementary
material.
IV. DISCUSSION
The current research documented the first-time spectral
photon-counting CT imaging of contrast-enhanced TB
lesions as a way of illustrating cutting-edge human transla-
tional, preclinical molecular imaging. This study compared
the results from spectral photon-counting CT (MARS spec-
tral CT) with micro-CT (SuperArgus). The total volume of
the healthy and disease-related lung tissue quantified by
spectral CT was comparable to the volume quantified by
micro-CT. Differences in tissue volume was due to using
different methodology to provide margins of error for each
modality. For micro-CT, a 5% margin was established by
previous research which examined multiple healthy lung tis-
sue samples [34]. For the spectral CT, only one healthy lung
tissue iodine dataset was available. Therefore, a margin of
error relating to the variation in measured iodine from the
calibration vials was calculated and added. The volume of
tissue calculation is sensitive to the margin of error; thus,
future experiments should scanmultiple healthy lung samples
with MARS to obtain a material-specific and statistically rel-
evant margin of error. This technique could further optimize
thresholding of spectral CT data and reduce differences in
the measurements. The current study was a proof-of-concept,
thus multiple samples were not scanned. Another possi-
ble reason for the difference in the measurements between
spectral CT and micro-CT is misidentification of materials;
lipid or paraffin wax misidentified as water or soft tissue.
MARS MD algorithm employs a constrained linear least
squares method, which is applied in the image domain using
the mass attenuation coefficient values from the calibration
phantom [36]. Future MD algorithms will be improved by
using a joint reconstruction process (not limited to either
projection- or image-domain) and if deep learning can be
incorporated [37], [38].
Traditional diagnostic modalities employed for TB include
microbiology,microscopy, andmolecular techniques (nucleic
acid test or acid-fast staining), all of which require biological
samples (blood, stool, or sputum cultures) [39]. Biological
samples may not accurately reflect the local biology at the
site of infection, thus, are often not sensitive enough as a
stand-alone diagnostic test (poor sensitivity: 45-85%) [35],
[40]. Furthermore, the requirement of sputum cultures lim-
its or delays diagnosis because TB bacterium is difficult
and slow to cultivate ex-vivo (2-8 weeks) [41]. Biopsies
(removal of tissue) are often the last resort for unequivocal
diagnosis. However, biopsies are invasive, generally limited
to the most accessible lesion, prone to sampling error, and
fail to capture the heterogeneous nature of TB infection.
Thus, like biological samples, biopsies provide a localized
indication of lesion composition, they do not report on the
entire disease. Clinically available imaging modalities can
provide whole tissue assessment and have a role depending
on the patient’s clinical profile. X-ray imaging is based on
anatomical changes; changes that are often delayed relative to
disease progression at the molecular level. Spectral photon-
counting CT provides more information in the form of tissue
characterization, as well as density. The benefit of spectral CT
also comes from its ability to be directly translated to clini-
cal human imaging. MARS preclinical systems use almost
the same technology, in terms of hardware and software,
as MARS clinical systems, which are currently being used
for human trials.
Bacterial-specific imaging is an active area of preclinical
research with encouraging results. The goal is to provide non-
invasive whole-body analysis using bacteria-specific imaging
probes. Patient outcomes could be significantly improved
by fast identification of infection and monitoring of disease
response to treatment. Several radio-labelled derivatives of
antibiotics for PET imaging have been investigated [42]–[44].
For PET, the selective metabolism of small molecules, such
as sugar, for differentiating bacterial infections from non-
infectious processes has been examined [43]. Unlike PET,
spectral CT does not require radioactive tracers for molecular
imaging. Therefore, the authors see the next step in taking
this proof-of-concept to actual application is imaging a non-
radioactive, high-Z atom functionalized by a key biomarker
of TB and/or TB-specific drug. Spectral photon-counting CT
could enable a more sensitive and specific research tool.
Functionalized or labelled high-Z nanoparticles with spectral
CT has been demonstrated [23], [26]. Disease severity, dis-
ease heterogeneity, and drug delivery could bemeasured [26].
With regards to drug development, translational research
using preclinical micro-CT plays a pivotal role in the man-
agement of TB, by assessing disease severity and evaluating
new effective anti-tuberculosis drug combinations for ther-
apy [35], [45], [46]. Micro-CT offers high resolution, low
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cost, and wide availability. Intensity histograms in HU are
used to provide tissue characterization, since diseased tissue
present abnormal densities in the organ of interest [32], [45],
[47]. Soft-tissue imaging, however, is limited, and character-
ization of abnormal X-ray densities associated with TB is
highly challenging in preclinical research [8], [9]. Contrast
material can be employed to enhance attenuation and assist
in 3D visualization of soft tissue and lesion composition.
Another potential advantage of spectral CT imaging
includes the reduction of biological variability (each animal
is utilized as its own control), acquiring data non-invasively,
repeated imaging if needed (non-toxic contrast should be
used), and a reduction in the number of animals required
for a study. Current micro-CT uses high tube currents which
limit the use of animals in longitudinal studies [9]. Future
studies can use MARS spectral photon-counting CT to per-
form longitudinal quantitative imaging that can be collected
from the same animal with low dose [48], and thus subtle
functional changes and development of structural changes
over time can be identified. To improve the current proof-of-
concept study and take our work a step closer to actual appli-
cation, we recommend future investigations compare contrast
uptake by TB lesions versus non-TB lung masses. This would
demonstrate the ability to distinguish TB lesions from non-
TB nodules, using spectral photon-counting CT. In addition,
we recommend imaging of functionalized pharmaceuticals
specific to pulmonary TB to measure drug delivery and test
the effectiveness of the targeting methods used. More precise
diagnosis, monitoring of therapy efficacy, and the develop-
ment of new and more effective drugs could be key to the
eradication of TB.
V. CONCLUSION
The results of this study support the idea that photon-counting
CT imaging is capable of molecular imaging when enhanced
by high-Z pharmaceuticals. The Medipix3RX detector oper-
ating four CSM energy bins provided sufficient spectral
information for the simultaneous differentiation of iodine,
water, and lipid (and a second high-Z contrast). In an ex-vivo
mouse model of chronic TB, detection of iodine contrast
enabled segmentation and volume quantification of healthy
and disease-related lung tissue. The results demonstrated the
potential clinical utility of photon-counting CT imaging for
molecular imaging in infectious lung diseases. In the future,
if a TB-specific drug were to be incorporated with a high-
Z nanoparticle, spectral CT could provide non-invasive eval-
uation of drug delivery and response to treatment. Such an
imaging platform would have the potential to assist diagnosis
and accelerate the development of novel therapies, which is
essential for the eradication of TB.
Photon-counting CT technology offers improved spatial
and energy resolution. Thus, it is a promising next step in the
evolution of CT.
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